U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H21N.ClH
Molecular Weight 275.8168
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENZPHETAMINE HYDROCHLORIDE

SMILES

C[C@@]([H])(Cc1ccccc1)N(C)Cc2ccccc2.Cl

InChI

InChIKey=ANFSNXAXVLRZCG-RSAXXLAASA-N
InChI=1S/C17H21N.ClH/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17;/h3-12,15H,13-14H2,1-2H3;1H/t15-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C17H21N
Molecular Weight 239.356
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Benzphetamine is a sympathomimetic agent with properties similar to dextroamphetamine. It is used in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m2 or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Presumably, benzphetamine produces its effects through mechanisms similar to amphetamine via induces synaptic vesicular amine transporter, but precise mechanism of action of benzphetamine is not known.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
BENZPHETAMINE HYDROCHLORIDE

Approved Use

Benzphetamine hydrochloride tablets are indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m2 or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Benzphetamine hydrochloride tablets are indicated for use as monotherapy only.

Launch Date

1.14523203E12
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.9 μg × min/mL
10 mg/kg 1 times / day multiple, intraperitoneal
dose: 10 mg/kg
route of administration: Intraperitoneal
experiment type: MULTIPLE
co-administered:
BENZPHETAMINE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13%
BENZPHETAMINE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Other AEs: Gastrointestinal signs and symptoms, Dizziness...
Other AEs:
Gastrointestinal signs and symptoms (5 patients)
Dizziness (4 patients)
Constipation (2 patients)
Nervousness (5 patients)
Pruritus (1 patient)
Dry mouth (3 patients)
Chest pain (1 patient)
Headache (1 patient)
Malaise (1 patient)
Fatigue (1 patient)
Appetite disorder (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Appetite disorder 1 patient
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Chest pain 1 patient
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Fatigue 1 patient
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Headache 1 patient
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Malaise 1 patient
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Pruritus 1 patient
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Constipation 2 patients
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Dry mouth 3 patients
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Dizziness 4 patients
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Gastrointestinal signs and symptoms 5 patients
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
Nervousness 5 patients
80 mg 3 times / day multiple, oral (max)
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 54
n = 20
Health Status: unhealthy
Condition: Obesity
Age Group: 54
Sex: F
Population Size: 20
Sources:
PubMed

PubMed

TitleDatePubMed
Characterization of rabbit liver P450IIE1 synthesized in transformed yeast cells.
1990 Oct
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
2003 Jan 1
The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation.
2005 Jun
Resonance Raman studies of cytochrome P450 2B4 in its interactions with substrates and redox partners.
2008 Mar 25
Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection.
2009 Jun
Patents

Patents

Sample Use Guides

Dosage should be individualized according to the response of the patient. The suggested dosage ranges from 25 to 50 mg one to three times daily. Treatment should begin with 25 to 50 mg once daily with subsequent increase in individual dose or frequency according to response. A single daily dose is preferably given in mid-morning or mid-afternoon, according to the patient's eating habits. In an occasional patient it may be desirable to avoid late afternoon administration. Use of benzphetamine hydrochloride is not recommended in individuals under 12 years of age.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:19:27 UTC 2021
Edited
by admin
on Sat Jun 26 16:19:27 UTC 2021
Record UNII
43DWT87QT7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENZPHETAMINE HYDROCHLORIDE
MI   ORANGE BOOK   VANDF  
Common Name English
BENZENEETHANAMINE, N,.ALPHA.-DIMETHYL-N-(PHENYLMETHYL)-, HYDROCHLORIDE (1:1), (.ALPHA.S)-
Common Name English
BENZFETAMINE HYDROCHLORIDE [WHO-DD]
Common Name English
BENZPHETAMINE HYDROCHLORIDE CIII
USP-RS  
Common Name English
PHENETHYLAMINE, N-BENZYL-N,.ALPHA.-DIMETHYL-, HYDROCHLORIDE, (+)-
Systematic Name English
BENZFETAMINE HYDROCHLORIDE
MART.   WHO-DD  
Common Name English
NSC-10937
Code English
(+)-BENZPHETAMINE HYDROCHLORIDE
Common Name English
BENZPHETAMINE HYDROCHLORIDE [MI]
Common Name English
BENZPHETAMINE HYDROCHLORIDE [USP-RS]
Common Name English
BENZPHETAMINE HYDROCHLORIDE [VANDF]
Common Name English
U-0441
Code English
BENZPHETAMINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
DIDREX
Brand Name English
(+)-N-BENZYL-N,.ALPHA.-DIMETHYLPHENETHYLAMINE HYDROCHLORIDE
Systematic Name English
BENZFETAMINE HYDROCHLORIDE [MART.]
Common Name English
BENZPHETAMINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
BENZPHETAMINE HCL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29728
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
NCI_THESAURUS C47795
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
DEA NO. 1228
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C61648
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY
CAS
5411-22-3
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY
DRUG BANK
DBSALT000832
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY
ECHA (EC/EINECS)
226-489-2
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY
ChEMBL
CHEMBL3545985
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY
FDA UNII
43DWT87QT7
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY
EPA CompTox
5411-22-3
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY
MERCK INDEX
M2391
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY Merck Index
PUBCHEM
11558159
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY
EVMPD
SUB00721MIG
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY
USP_CATALOG
1059003
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY USP-RS
RXCUI
142425
Created by admin on Sat Jun 26 16:19:28 UTC 2021 , Edited by admin on Sat Jun 26 16:19:28 UTC 2021
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY